Artwork system may help cut generic launch times
PD, which is the software arm of the Perigord group, said that because time to market is so critical for the generic drug industry, delays during the design and production of packaging can have a dramatic impact on commercial success. The firm argued that the on-line collaborative workspace and storage areas provided by its GL-AMS system can significantly reduce development time.
PD also believes that its system, which was specifically developed for generic drugmakers, will allow such companies to make more use of contract manufacturing organisations (CMO) because it affords greater control of production output.
Alan Leamy, PD’s CEO, commented that: “Once a drug comes off patent the window of opportunity to secure own-label manufacturing contracts is naturally very tight.” He added that: commercial success is determined by how rapidly a “fully packaged and fully compliant” generic product can be brought to market.
Leamy went on to say that: "This challenge is exacerbated by the complexity of the product and also the stringent compliancy requirements. The GL-AMS Global Artwork Management System quickly and seamlessly brings outsource partners into the control and collaboration loop, enabling generics manufacturers to take on extra capacity with greater ease and confidence"
Improved flexibility design solutions
The GL-AMS system provides generics firms and outsourcing partners with a central repository for digital artwork assets. The platform is designed to integrate with all aspects of the artwork lifecycle process in a manner that is compliant with all relevant pharmaceutical industry standards.
The Connecticut-headquartered firm argued that GL-AMS can eliminate delays for signed off proofs, provide an improved audit and accountability trail and can offer greater control of manufacture that allows users to stop and start production to suit capacities or last minute regulatory changes.
In addition, PD believes that because GL-AMS exists on a secure Internet site, manufacturers can quickly assign print projects to new suppliers without the need to acquire properties from previous suppliers, thereby reducing project time.
"It's not always easy getting your art properties returned by former print suppliers," Leamy explained. "There's naturally less of a rush when there is no business incentive attached. GL-AMS retains access to the finalized print product and this makes generic drug manufacturers swifter and more versatile to work with a range of outsource partners"
